Table 2.
Procedural details and treatment outcomes in the matched population
| Variable | Lipiodol-TACE, n = 101 | DEB-TACE, n = 101 | p | |
|---|---|---|---|---|
| Dose of doxorubicin | Mean ± SD | 54.5 ± 14.3 | 62.7 ± 24.0 | 0.0035 |
| Range | 12 - 75 | 25 - 150 | ||
| Dose of lipiodol (mL) | Mean ± SD | 14.6 ± 6.1 | NA | NA |
| Range | 3 - 30 | |||
| Number of beads’ vials | 1/2 | NA | 80/21 | NA |
| Hospitalization (days) | Mean ± sd | 2.5 ± 2.3 | 1.9 ± 1.7 | 0.03 |
| Periprocedural complications | No | 74 (73.3) | 90 (89.1) | 0.03 |
| Grade 1 | 15 (14.8) | 5 (4.9) | ||
| Grade 2 | 10 (9.9) | 4 (4.0) | ||
| Grade 3 | 2 (2.0) | 1 (1.0) | ||
| Grade 4 | 0 | 1 (1.0) | ||
| 1-month target tumor response | CR | 53 (52.5) | 52 (51.5) | 0.90 |
| PR | 30 (29.7) | 34 (33.6) | ||
| SD | 15 (14.8) | 13 (12.9) | ||
| PD | 3 (3.0) | 2 (2.0) | ||
| 1-month overall tumor response | CR | 44 (43.6) | 46 (45.5) | 0.97 |
| PR | 28 (27.7) | 29 (28.7) | ||
| SD | 15 (14.8) | 14 (13.9) | ||
| PD | 14 (13.9) | 12 (11.9) | ||
| Best target tumor response | CR | 63 (62.4) | 62 (61.3) | 0.81 |
| PR | 26 (25.7) | 29 (28.7) | ||
| SD | 11 (10.9) | 8 (8.0) | ||
| PD | 1 (1.0) | 2 (2.0) | ||
| Follow-up duration (months) | Median | 30.6 | 33.8 | 0.82 |
| Range | 2.1-123.1 | 1.5-105.1 | ||
| N. of treatments post-TACE | Mean ± sd | 1.41 ± 1.9 | 1.03 ± 1.34 | 0.11 |
| Post-TACE Liver transplantation (yes) | 14 (13.9) | 23 (22.8) | 0.10 |
When not otherwise specified, data are given as numbers (and percentages)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NR, not reached